William Blair analyst Myles Minter has reiterated their bullish stance on NTLA stock, giving a Buy rating on April 21.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Myles Minter has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ promising developments in their clinical trials and strategic planning. The company’s NTLA-2002 therapy for hereditary angioedema (HAE) is progressing well, with patient enrollment in the Phase III HAELO study underway and expectations set for completion by the third quarter of 2025. This therapy could potentially become the first in vivo CRISPR-based treatment to receive FDA approval, marking a significant milestone for Intellia.
Minter also notes the encouraging progress in the Phase III MAGNITUDE study for NTLA-2001, aimed at treating ATTR cardiomyopathy (ATTR-CM). The enrollment is ahead of expectations, reflecting strong interest despite competition from other treatments. Additionally, the Phase III MAGNITUDE-2 trial for ATTR polyneuropathy (ATTR-PN) is advancing, with the first patient dosed in April. The potential for interim analyses in these trials could provide further insights into their success, reinforcing the company’s strategic positioning and potential for future growth.
Minter covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Alnylam Pharma, and Arcturus Therapeutics. According to TipRanks, Minter has an average return of 5.0% and a 48.62% success rate on recommended stocks.
In another report released on April 21, Wolfe Research also upgraded the stock to a Buy with a $21.00 price target.